Clinical Trial Update: IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating IBI343 in combination with chemotherapy as neoadjuvant therapy for borderline resectable pancreatic cancer. The study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer
• Pancreatic Cancer

Drugs mentioned

• IBI343

Snippet

Sponsor: Zhejiang University | Conditions: Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING